CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
REVENUES:
Total revenues	$ 1,704,048	$ 1,491,212	$ 1,313,646
OPERATING EXPENSES:
Cost of sales	359,466	315,264	241,786
Research and development	715,007	696,328	610,753
Selling, general and administrative	680,924	604,353	554,336
Intangible asset amortization and contingent consideration	74,108	48,791	46,471
Gain on sale of intangible assets	(25,000)	(50,000)	(125,000)
Total operating expenses	1,804,505	1,614,736	1,328,346
LOSS FROM OPERATIONS	(100,457)	(123,524)	(14,700)
Equity in the loss of BioMarin/Genzyme LLC	(587)	(553)	(1,291)
Interest income	22,748	22,831	14,853
Interest expense	(23,460)	(43,664)	(42,707)
Other income, net	6,945	2,205	7,970
LOSS BEFORE INCOME TAXES	(94,811)	(142,705)	(35,875)
Provision for (benefit from) income taxes	(70,963)	(65,494)	81,167
NET LOSS	$ (23,848)	$ (77,211)	$ (117,042)
NET LOSS PER SHARE, BASIC (in usd per share)	$ (0.13)	$ (0.44)	$ (0.67)
NET LOSS PER SHARE, DILUTED (in usd per share)	$ (0.13)	$ (0.44)	$ (0.67)
Weighted average common shares outstanding, basic	179,039	177,061	174,427
Weighted average common shares outstanding, diluted	179,039	177,268	174,427
Product
REVENUES:
Total revenues	$ 1,661,043	$ 1,470,356	$ 1,270,445
Royalty and Other Revenues
REVENUES:
Total revenues	$ 43,005	$ 20,856	$ 43,201